vs
Side-by-side financial comparison of Baxter International (BAX) and J.M. Smucker Company (The) (SJM). Click either name above to swap in a different company.
Baxter International is the larger business by last-quarter revenue ($3.0B vs $2.3B, roughly 1.3× J.M. Smucker Company (The)). J.M. Smucker Company (The) runs the higher net margin — 10.4% vs -37.9%, a 48.3% gap on every dollar of revenue. On growth, Baxter International posted the faster year-over-year revenue change (458.0% vs 2.6%). Over the past eight quarters, J.M. Smucker Company (The)'s revenue compounded faster (2.2% CAGR vs -9.0%).
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois.
The J.M. Smucker Company, also known as Smucker's, is an American manufacturer of food and beverage products. Headquartered in Orrville, Ohio, the company was founded in 1897 as a maker of apple butter. J.M. Smucker currently has three major business units: consumer foods, pet foods, and coffee. Its flagship brand, Smucker's, produces fruit preserves, peanut butter, syrups, frozen crustless sandwiches, and ice cream toppings.
BAX vs SJM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $2.3B |
| Net Profit | $-1.1B | $241.3M |
| Gross Margin | 19.4% | 37.3% |
| Operating Margin | -24.5% | 18.0% |
| Net Margin | -37.9% | 10.4% |
| Revenue YoY | 458.0% | 2.6% |
| Net Profit YoY | -120.3% | 1084.9% |
| EPS (diluted) | $-2.21 | $2.26 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.0B | $2.3B | ||
| Q3 25 | $2.8B | $2.1B | ||
| Q2 25 | $2.8B | $2.1B | ||
| Q1 25 | $2.6B | $2.2B | ||
| Q4 24 | $533.0M | $2.3B | ||
| Q3 24 | $2.7B | $2.1B | ||
| Q2 24 | $3.8B | $2.2B | ||
| Q1 24 | $3.6B | $2.2B |
| Q4 25 | $-1.1B | $241.3M | ||
| Q3 25 | $-46.0M | $-43.9M | ||
| Q2 25 | $91.0M | $-729.0M | ||
| Q1 25 | $126.0M | $-662.3M | ||
| Q4 24 | $-512.0M | $-24.5M | ||
| Q3 24 | $140.0M | $185.0M | ||
| Q2 24 | $-314.0M | $245.1M | ||
| Q1 24 | $37.0M | $120.4M |
| Q4 25 | 19.4% | 37.3% | ||
| Q3 25 | 33.5% | 22.5% | ||
| Q2 25 | 35.3% | 38.4% | ||
| Q1 25 | 32.8% | 40.2% | ||
| Q4 24 | 25.0% | 39.0% | ||
| Q3 24 | 38.3% | 37.5% | ||
| Q2 24 | 37.5% | 41.4% | ||
| Q1 24 | 38.6% | 36.9% |
| Q4 25 | -24.5% | 18.0% | ||
| Q3 25 | 6.1% | 2.2% | ||
| Q2 25 | 6.8% | -27.9% | ||
| Q1 25 | 2.2% | -27.2% | ||
| Q4 24 | -25.5% | 7.5% | ||
| Q3 24 | 5.7% | 16.4% | ||
| Q2 24 | -5.0% | 18.4% | ||
| Q1 24 | 5.2% | 13.3% |
| Q4 25 | -37.9% | 10.4% | ||
| Q3 25 | -1.6% | -2.1% | ||
| Q2 25 | 3.2% | -34.0% | ||
| Q1 25 | 4.8% | -30.3% | ||
| Q4 24 | -96.1% | -1.1% | ||
| Q3 24 | 5.2% | 8.7% | ||
| Q2 24 | -8.2% | 11.1% | ||
| Q1 24 | 1.0% | 5.4% |
| Q4 25 | $-2.21 | $2.26 | ||
| Q3 25 | $-0.09 | $-0.41 | ||
| Q2 25 | $0.18 | $-6.86 | ||
| Q1 25 | $0.25 | $-6.22 | ||
| Q4 24 | $-0.99 | $-0.23 | ||
| Q3 24 | $0.27 | $1.74 | ||
| Q2 24 | $-0.62 | $2.31 | ||
| Q1 24 | $0.07 | $1.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.0B | — |
| Total DebtLower is stronger | $9.5B | $7.0B |
| Stockholders' EquityBook value | $6.1B | $6.1B |
| Total Assets | $20.1B | $17.6B |
| Debt / EquityLower = less leverage | 1.55× | 1.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0B | — | ||
| Q3 25 | $1.7B | — | ||
| Q2 25 | $1.7B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $1.8B | — | ||
| Q3 24 | $1.4B | — | ||
| Q2 24 | $2.1B | — | ||
| Q1 24 | $3.0B | — |
| Q4 25 | $9.5B | $7.0B | ||
| Q3 25 | — | $7.0B | ||
| Q2 25 | — | $7.0B | ||
| Q1 25 | — | $7.4B | ||
| Q4 24 | $10.4B | $7.8B | ||
| Q3 24 | $10.4B | $7.8B | ||
| Q2 24 | $10.4B | $7.8B | ||
| Q1 24 | $11.1B | $8.1B |
| Q4 25 | $6.1B | $6.1B | ||
| Q3 25 | $7.2B | $5.9B | ||
| Q2 25 | $7.3B | $6.1B | ||
| Q1 25 | $7.1B | $6.9B | ||
| Q4 24 | $7.0B | $7.6B | ||
| Q3 24 | $7.9B | $7.8B | ||
| Q2 24 | $7.6B | $7.7B | ||
| Q1 24 | $8.2B | $7.6B |
| Q4 25 | $20.1B | $17.6B | ||
| Q3 25 | $21.1B | $17.7B | ||
| Q2 25 | $21.0B | $17.6B | ||
| Q1 25 | $21.3B | $18.4B | ||
| Q4 24 | $25.8B | $20.0B | ||
| Q3 24 | $26.7B | $20.3B | ||
| Q2 24 | $26.3B | $20.3B | ||
| Q1 24 | $27.8B | $20.2B |
| Q4 25 | 1.55× | 1.16× | ||
| Q3 25 | — | 1.19× | ||
| Q2 25 | — | 1.16× | ||
| Q1 25 | — | 1.07× | ||
| Q4 24 | 1.49× | 1.02× | ||
| Q3 24 | 1.33× | 1.00× | ||
| Q2 24 | 1.37× | 1.01× | ||
| Q1 24 | 1.36× | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $584.0M | $346.5M |
| Free Cash FlowOCF − Capex | — | $280.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 2.8% |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | — | $635.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $584.0M | $346.5M | ||
| Q3 25 | $237.0M | $-10.6M | ||
| Q2 25 | $217.0M | $393.9M | ||
| Q1 25 | $-193.0M | $239.4M | ||
| Q4 24 | $488.0M | $404.2M | ||
| Q3 24 | $253.0M | $172.9M | ||
| Q2 24 | $115.0M | $428.1M | ||
| Q1 24 | $163.0M | $406.5M |
| Q4 25 | — | $280.2M | ||
| Q3 25 | — | $-94.9M | ||
| Q2 25 | — | $298.9M | ||
| Q1 25 | — | $151.3M | ||
| Q4 24 | — | $317.2M | ||
| Q3 24 | — | $49.2M | ||
| Q2 24 | — | $297.5M | ||
| Q1 24 | — | $249.6M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -4.5% | ||
| Q2 25 | — | 13.9% | ||
| Q1 25 | — | 6.9% | ||
| Q4 24 | — | 14.0% | ||
| Q3 24 | — | 2.3% | ||
| Q2 24 | — | 13.5% | ||
| Q1 24 | — | 11.2% |
| Q4 25 | — | 2.8% | ||
| Q3 25 | — | 4.0% | ||
| Q2 25 | — | 4.4% | ||
| Q1 25 | — | 4.0% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | — | 5.8% | ||
| Q2 24 | — | 5.9% | ||
| Q1 24 | — | 7.0% |
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | — | ||
| Q2 25 | 2.38× | — | ||
| Q1 25 | -1.53× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.81× | 0.93× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | 4.41× | 3.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BAX
| Other | $1.5B | 51% |
| Infusion Therapies And Technologies | $543.0M | 18% |
| Pharmaceutical Compounding | $316.0M | 11% |
| Front Line Care | $219.0M | 7% |
| Injectables And Anesthesia | $190.0M | 6% |
| Advanced Surgery | $177.0M | 6% |
SJM
| U.S.Retail Frozen Handheld And Spreads | $461.1M | 20% |
| U.S.Retail Pet Foods | $413.2M | 18% |
| Handheld Frozen Sandwiches | $262.9M | 11% |
| Sweet Baked Snacks | $256.1M | 11% |
| Pet Snacks | $232.0M | 10% |
| Cat Food | $197.2M | 8% |
| Peanut Butter | $187.1M | 8% |
| CA | $94.5M | 4% |
| Fruit Spreads | $92.2M | 4% |
| Other | $50.5M | 2% |
| Portion Control | $50.1M | 2% |
| All Other International | $33.2M | 1% |
